OPEN ACCESS Freely available online

Journal of Leukemia

Perspective

A Short Note on Childhood Leukemia

Voltaire Djia*

Department of Social Sciences, Humanities and Social Sciences, University of Yaounde 1, Cameroon

DESCRIPTION

Pediatric leukemia is a kind of childhood cancer in which a youngster develops leukemia. In 2018, juvenile leukemia was the most frequent malignancy in children aged 0–14, accounting for 29 percent of tumors in this age group. In children, there are several types of leukemia, the most prevalent of which is Acute Lymphoblastic Leukemia (ALL), followed by Acute Myeloid Leukemia (AML). Survival rates vary depending on the type of leukemia, but with ALL, they can be as high as 90%.

Leukemia is a blood cancer that is classified as a hematological malignancy. It starts in the bone marrow, which is the soft interior part of the bone where new blood cells are produced. The bone marrow of a child with leukemia creates white blood cells that do not mature properly. Normal healthy cells can only replicate if there is enough room for them to do so. The body will control cell production by sending out signals when it is time to cease. The cells of a child with leukemia do not respond to the signals that instruct them when to cease producing cells and when to stop producing them. When the bone marrow becomes overcrowded, it becomes difficult to produce other blood cells. Excessive weariness, easy bruising or bleeding, bone discomfort, and paleness are all common signs and symptoms of juvenile leukemia. Leukemia is classified as either "acute," which progresses swiftly, or "chronic," which progresses slowly. The vast majority of childhood leukemia's are acute, and adults are more likely than children to develop chronic leukemia's. Acute Leukemia's are characterized by rapid onset and progression over periods of days to weeks. Chronic Leukemia develop more slowly (months) than acute leukemia's, but they are more difficult to treat. Some of the most common kinds of leukemia in children are listed here. The majority of cases of pediatric leukemia have an unknown cause. The majority of children with leukemia have no identified risk factors. Childhood Acute Lymphoblastic Leukemia (ALL) is thought to be caused by a two-step process that begins with a prenatal genetic alteration and continues with virus exposure. While this notion is plausible, there is currently insufficient data in patients to support or reject the link between infection and the development of ALL. There is proof that maternal alcohol intake is linked to the development of AML in children. Indoor pesticide exposure has also been connected to childhood leukemia development. Coffee use during pregnancy (2-3 cups per day or more) has also been connected to infantile leukemia. Allergies have also been connected to the development of juvenile leukemia; however current research does not support this theory.

Treatment for childhood leukemia is determined by a variety of factors, including the type of leukemia, its characteristics, prognostic characteristics (children with worse prognostic characteristics receive more aggressive therapy; see the Prognosis section), response to therapy, and the extent of the disease at the time of diagnosis. A team of health care professionals, including pediatric oncologists, social workers, pediatric nurse specialists, and doctors, are usually in charge of treatment. Insecticide exposure inside has also been connected to the onset of children leukemia's. While the type of leukemia and the circumstances stated above define the particular treatment plan, there are five types of medicines that are commonly used to treat all juvenile leukemia's. Four of them are established treatments, and one is currently being tested in a clinical trial. Chemotherapy, stem cell transplant, radiation therapy, and targeted therapy are the four types of treatments that have traditionally been employed. Immunotherapy is a sort of treatment that is now being tested in clinical studies.

Correspondence to: Voltaire Djia, Department of Social Sciences, Humanities and Social Sciences, University of Yaounde 1, Cameroon; E-mail: djiaprof@gmail.com

Received: 18-Feb-2022, Manuscript No. Jlu-22-15149; **Editor assigned:** 21-Feb-2022, PreQC No. Jlu-22-15149 (PQ); **Reviewed:** 7-Mar-2022, QC No. Jlu-22-15149; **Revised:** 11-Mar-2022, Manuscript No. Jlu-22-15149 (R); **Published:** 18-Mar-2022, DOI: 10.35248/2329-6917.10.1.283

Citation: Djia V (2022) A Short Note on Childhood Leukemia. J Leuk. 10:283